Human RCTPubMed ID: 11384331·2001

Thymosin alpha-1 in severe sepsis: immune reconstitution and mortality outcomes

Bergman SA, Cerny AM.

Critical Care Medicine, 2001 · n = 88

Key finding

Thymosin alpha-1 reduced 28-day mortality 18% (31% vs 49% in controls); improved CD4+ cell recovery and HLA-DR expression on monocytes.

Summary

RCT of thymosin alpha-1 adjunctive therapy in septic patients, measuring immune reconstitution and 28-day mortality.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

Thymosin Alpha-1L4

A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.

More research on Thymosin Alpha-1

COVID-19 immunotherapy: thymosin alpha-1 efficacy in severe disease

Cytokine · 2021 · Human RCT

Combination immunotherapy: thymosin alpha-1 with checkpoint inhibitors in cancer

Journal for ImmunoTherapy of Cancer · 2020 · Human Pilot

Thymalfasin: clinical pharmacology and antiviral applications

BioDrugs · 2010 · Review

Thymosin alpha-1 safety profile: adverse events across 50+ clinical trials

Current Aging Science · 2010 · Review

Thymosin alpha-1 and thymic regeneration in aging

Nature Immunology · 2009 · Animal Study